Table 3.
Univariate analysis of baseline clinical and histopathologic variables.
| Rate of Upgrading per year of follow-up (95% CI) | HR (95% CI) | p | |
|---|---|---|---|
| Gleason score | |||
| 3+3 | 0.06 (0.03–0.09) | ||
| 3+4 | 0.23 (0.14–0.38) | 4.65 (2.32–9.34) | < 0.01 |
|
| |||
| PSA | |||
| <10 ng/mL | 0.08 (0.06–0.12) | ||
| ≥10 ng/mL | 0.15 (0.06–0.41) | 1.97 (0.69–5.64) | NS |
|
| |||
| PSA % free | |||
| >10 % | 0.06 (0.04–0.10) | ||
| ≤10% | 0.22 (0.13–0.39) | 3.75 (1.85–7.60) | < 0.01 |
|
| |||
| PSA density | |||
| < 0.15 ng/mL/cm3 | 0.06 (0.04–0.10) | ||
| ≥ 0.15 ng/mL/cm3 | 0.20 (0.12–0.35) | 3.43 (1.68–7.05) | < 0.01 |
|
| |||
| MRI grade | |||
| < 3 (referent) | 0.08 (0.03–0.17) | ||
| 3, 4, or 5 | 0.09 (0.06–0.13) | 1.23 (0.51–2.98) | NS |
| 5 | 0.35 (0.13–0.94) | 5.16 (1.79–14.87) | < 0.01 |
|
| |||
| Maximum cancer core length | |||
| <4 mm | 0.08 (0.05–0.12) | ||
| ≥4 mm | 0.12 (0.06–0.24) | 1.53 (0.71–3.30) | NS |
|
| |||
| Maximum % tumor involvement in any core | |||
| < 60% | 0.09 (0.06–0.13) | ||
| ≥60% | 0.05 (0.01–0.34) | 1.99 (0.27–14.59) | NS |
|
| |||
| Number of positive cores | |||
| ≤ 3 | 0.08 (0.06–0.11) | ||
| > 3 | 0.17 (0.06–0.44) | 2.26 (0.78–6.54) | NS |